Treating Localized Prostate Cancer: Long-Term Outcomes from a Randomized Trial

At 15 years, cancer-specific mortality was about 3% in all three groups — prostatectomy, radiotherapy, and active surveillance.

In the ProtecT trial, 1643 men with localized, mostly low-risk prostate cancer (77% with Gleason score of 6) were randomized to radical prostatectomy, radiotherapy with neoadjuvant androgen deprivation, or active surveillance based primarily on serial prostate-specific antigen (PSA) testing. In previously published findings, prostate cancer–specific mortality (≈1%) and overall mortality (≈10%) were similar in the three groups at 10 years (NEJM JW Gen Med Nov 1 2016 and N Engl J Med 2016; 375:1415, 1425).

Now, researchers report outcomes after median follow-up of 15 years:

Prostate cancer–specific mortality was similar in the three groups (≈3%).
Overall mortality was similar in all groups (≈22%).
Metastases developed more commonly in the active-…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Treating Localized Prostate Cancer: Long-Term Outcomes from a Randomized Trial

Topics

Reviewing Author